| P/E (FY) | — | Sales (TTM) | $16.0M |
| Earnings (TTM) | -$2.4M | ROE | — |
| Net Margin | −61.07% | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | 21.70% |
| Market Cap | $2.3M | Trading Days | 2552 |
| 52W High | 0.75 |
| 52W Low | 0.09 |
| % Off High | −84.83% |
| YTD | −61.90% | 1Y | −71.43% |
| 3Y | −95.78% | 5Y | −99.46% |
| 10Y | −99.37% | Since incept. (ann.) | −37.67% |
Technology Fees 90% · Device Sales 10%
| Ann. Volatility (1Y) | 136.05% | Ann. Volatility (3Y) | 144.46% |
| Sharpe (1Y) | −0.23 | Sharpe (3Y) | −0.04 |
| Max Drawdown (1Y) | −86.41% | Max Drawdown (3Y) | −96.41% |
| Beta (3Y, vs SPY) | −0.09 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| TNON | Tenon Medical, Inc. | $2.2M | — |
| GCTK | Glucotrack, Inc. | $1.9M | 0.0 |
| IVF | INVO Fertility, Inc. | $1.8M | — |
| AEMD | AETHLON MEDICAL INC | $1.3M | — |
| NXGL | NEXGEL, INC. | $4.0M | — |
| PFSA | Profusa, Inc. | $4.8M | — |
| CODX | Co-Diagnostics, Inc. | $5.1M | — |
| BJDX | Bluejay Diagnostics, Inc. | $1.0M | — |
| SNOA | Sonoma Pharmaceuticals, Inc. | $5.5M | — |
| VVOS | Vivos Therapeutics, Inc. | $5.8M | — |
| LYRA | Lyra Therapeutics, Inc. | $887,441 | — |
| SINT | Sintx Technologies, Inc. | $6.7M | — |
